Pharmacology of Risperidone – Regulatory and marketing issues

Regulatory issues

Various regulatory issues could influence the availability and use of any medication in the society. Such issues affect both the access to the drug and also have implications for health practitioners involved in the diagnosis and treatment of various psychoses for which risperidone is used.

In New Zealand risperidone, which is marketed under the brand name Risperon, is a prescription only drug. (19). It is approved for treatment of acute and chronic schizophrenia and related psychoses, treatment and control of bipolar mania disorder, and treatment of conduct and other disruptive behaviour. (19). Potential drug abuse has not been documented in literature hence there might be no capacity for use of the drug in such circumstances. Other regulatory aspects of risperidone in New Zealand are as in other medications, where pharmaceutical companies that opt to provide consumer medicine information (CMI) in fulfilling the consumers right to access such information entrenched in Code of Health and Disability Services Consumers’ Rights; must do so in accordance with the guidelines provided by Medsafe – the regulatory authority that ensures the safety of medicines and medical devices in New Zealand (19).

Marketing and National access issues and cost issues

Risperidone is marketed under the brand name Risperon® in New Zealand (19). Currently, from available documentation (20) no other medications are marketed under a similar brand thus risperidone use does not bring about confusion in the market. Various outlets exist where Risperon can be obtained with prescription details thus no major access issues exist with regard to the drug. Similarly cost issues have not been documented with regard to risperidone.

References

  1. Garland, M. Spoiled for choice? The importance of selecting the right anti-psychotic agent. Irish Medical Times [Internet]. 2006 Jan 13 [cited 2010 Sept 9]. Available from ProQuest: http://tinyurl.com/379scjx
  2. Johnsen E, Kroken, RA, Wentzel-Larsen T, Jorgensen HA. Effectiveness of second-generation antipsychotics: a naturalistic, randomized comparison of olanzapine, quetiapine, risperidone, and ziprasidone. BMC Psychiatry [Internet]. 2010 Mar [cited 2010 Sept 9]; 10(26): [13 pp.]. Available from: http://www.biomedcentral.com/content/pdf/1471-244X-10-26.pdf
  3. Aman MG, Vinks AA, Remmerie B, Mannaert E, Ramadan Y, Masty J, et al. Plasma pharmacokinetic characteristics of risperidone and their relationship to saliva concentrations in children with psychiatric or neurodevelopmental disorders. Clin Ther [Internet]. 2007 May [cited 2010 Sept 9]; 29(7): 1476-1486. Available from ScienceDirect: http://tinyurl.com/3a6o2s5
  4. van Schaick EA, Lechat P, Remmerie BMM, Ko G, Lasseter KC, Mannaert E. Pharmacokinetic comparison of fast-disintegrating and conventional tablet formulations of risperidone in healthy volunteers. Clin Ther [Internet]. 2003 [cited 2010 Sept 9]; 25(6): 1687-1699. Available from ScienceDirect: http://tinyurl.com/32r9yv5
  5. Janssen Pharmaceutica Products, L.P. Risperdal® (risperidone) tablets/oral solution; Risperdal® M-TAB® (risperidone) orally disintegrating tablets; Risperdal® Consta® (risperidone) long-acting injection [Internet]. Titusville, New Jersey: Janssen: cc2003. [updated 2005 Feb; cited 2010 Sept 9]. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2005/020272s042,020588s030,021444s016,021346s010lbl.pdf
  6. National Center for Biotechnology Information. PubChem Compound [Internet]. Maryland: NCBI. [date unknown]. [cited 2010 Sept 9]. Available from: http://www.ncbi.nlm.nih.gov/sites/entrez
  7. RxList Inc. Risperdal® [Internet]. [Place unknown]: RxList Inc.; c2009 [updated 2008 Mar 9; cited 2010 Sep 10]; [about 13 screens]. Available from: http://www.rxlist.com/risperdal-drug.htm
  8. Zhou Z, Li X, Peng H, Yu X, Yang M, Su F, et al. Multiple dose pharmacokinetics of risperidone and 9-hydroxyrisperidone in Chinese female patients with schizophrenia. Acta Pharmacol Sin [Internet]. 2006 Mar [cited 2010 Sept 9]; 27(3): 381-386. Available from: http://www.nature.com/aps/journal/v27/n3/pdf/aps200649a.pdf
  9. Alavijeh MS, Chishty M, Qaiser MZ, Palmer AM. Drug metabolism and pharmacokinetics, the blood-brain barrier, and central nervous system drug discovery. NeuroRx [Internet]. 2005 Oct [cited 2010 Sept 9]; 2(4): 554-71. Available from PubMed Central: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1201315/pdf/neurorx002000554.pdf
  1. Lindenmayer J, Khan A, Eerdekens M, Hove IL, Kushner S. Long-term safety and tolerability of long-acting injectable risperidone in patients with schizophrenia or schizoaffective disorder. Eur Neuropsychopharmacol [Internet]. 2007 [cited 2010 Sept 10]; 17(2): 138-144. Available from ScienceDirect http://tinyurl.com/2w58dzx
  2. Cada DJ, Levien T, Baker DE. Risperidone long-acting injection. Hosp Pharm [Internet]. 2004 [cited 2010 Sept 10]; 39(4): 353-365. Available from: http://www.factsandcomparisons.com/assets/hospitalpharm/apr2004_form.pdf
  3. Eerdekens M, Hove IV, Remmerie B, Mannaert E. Pharmacokinetics and tolerability of long-acting risperidone in schizophrenia. Schizophr Res [internet]. 2004 Feb [cited 2010 Sept 10]; 70(1): 91-100. Available from ScienceDirect: http://tinyurl.com/36xjoqw
  4. Knox ED, Stimmel GL. Clinical review of a long-acting, injectable formulation of Risperidone. Clin Ther [internet]. 2004 [cited 2010 Sept 10]; 26:1994–2002. Available from ScienceDirect: http://tinyurl.com/2wwp3e2
  5. Feng Y, Pollock BG, Coley K, Marder S, Miller D, Kirshner M. Population pharmacokinetic analysis for risperidone using highly sparse sampling measurement from CATIE study. Br J Clin Pharmacol [Internet]. 2008 Sep [cited 2010 Sept 10]; 66(5): 629-639. Available from: http://onlinelibrary.wiley.com/doi/10.1111/j.1365-2125.2008.03276.x/pdf
  6. Drugs.com. Risperidone. [internet].Virginia: Drugs.com. cc2000-2010. [updated 2010 Sep 2; cited 2010 Sep 10]. Available from: http://www.drugs.com/ppa/risperidone.html
  7. Farde L. Brain imaging of schizophrenia – the dopamine hypothesis. Schizophr Res [internet]. 1997 Dec [cited 2010 Sept 10]; 28(2/3): 157-162. Available from ScienceDirect: http://tinyurl.com/36ej46q
  8. Laruelle M, Abi-Dargham A, Dyck C, Gil R, D’Souza DC, Krystal J, et al. Dopamine and serotonin transporters in patients with schizophrenia: An imaging study with [123I]β-CIT. Biol Psychiatry [internet]. 2000 [cited 2010 Sept 10]; 47(5): 371-379. Available from ScienceDirect: http://tinyurl.com/3a7huvc
  9. Meltzer HY, Li Z, Kaneda Y, Ichikawa J. Serotonin receptors: their key role in drugs to treat schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry [internet]. 2003. [cited 2010 Sept 10]; 27(7): 1159-1172. Available from ScienceDirect: http://tinyurl.com/36azzym
  10. Maylan New Zealand Ltd. New Zealand consumer medicine information: Risperon – risperidone 1mg/mL oral solution [internet]. Wellington: Medsafe. 2009 Aug 13. [cited 2010 Sept 10]. Available from http://www.medsafe.govt.nz/Consumers/cmi/r/Risperonsoln.pdf
  11. Consumer medicine information [internet]. Wellington: Medsafe.[date unknown] [cited 2010 Sept 10].Available from: http://www.medsafe.govt.nz/Profs/CMI.asp

 

 

 

 

 

 

find the cost of your paper